Shares of NovoCure Limited (NVCR) are up 15% following the company's announcement of positive results from the phase 3 METIS clinical trial.
NVCR is trading on the Nasdaq at $15.15, up 15.88% or $2.08 per share. It has traded between $10.87 and $83.60 in the past 52-week period.
The trial confirmed that combining Tumor Treating Fields (TTFields) therapy with supportive care significantly prolongs the time to intracranial progression in patients with brain metastases from non-small cell lung cancer after stereotactic radiosurgery.
Patients receiving TTFields therapy and supportive care showed a median time to intracranial progression of 21.9 months, compared to 11.3 months for those receiving supportive care alone.
Novocure plans to submit these findings to regulatory authorities, publish them in a peer-reviewed scientific journal, and present them at an upcoming scientific congress.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.